Archive

Sizwe Hosmed’s regulatory allegations highlight claims of corruption, sabotage and racial bias in South Africa’s medical scheme industry.

Aspen Pharmacare is lining up a generic semaglutide launch in Canada, promising big discounts, and widening GLP-1 access.

Finance Minister Enoch Godongwana urged a truce in the NHI legal challenges, but political fault lines keep negotiations fragile.

Finance Minister Godongwana urges the settlement of NHI legal challenges to fast‑track universal healthcare and ease delays from court cases.

US healthcare spending in 2024 jumped 7.2% to $5.3 trillion, driven by rising insurance enrolment, service use, and administrative costs.

Aspen Pharmacare business sale boosts investor confidence. A strategic pivot following a turbulent 2025 rebuilds financial flexibility.

Hospital-acquired infections remain untracked nationally, risking thousands of preventable deaths and silent outbreaks in public hospitals.

Discovery Health claims will now be covered by the scheme after a processing error led to member outcry and regulatory scrutiny.

European drug pricing dispute heats up as pharma giants demand higher returns after US price cuts. Tensions are on the rise.

Discovery Health claims error prompts backlash as 16,000 members face repayments. Critics question the administrative failure.

GEMS tariff intervention planned as government responds to sharp price hikes affecting public service members and affordability pressures.